Seattle Genetics | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
AbbVie USD 10.71B 458M 2024-12
Acadia Pharmaceuticals USD 223.92M 13.87M 2025-03
Agios Pharmaceuticals USD 7.64M 1.83M 2025-03
Amgen USD 5.54B 430M 2025-03
Astellas Pharma JPY 382.44B 36.45B 2025-03
Bayer EUR 8.11B 2.11B 2025-03
Biogen USD 1.87B 44.1M 2024-12
BioMarin Pharmaceutical USD 593.59M 17.59M 2025-03
Bristol-Myers Squibb USD 8.18B 947M 2025-03
Celldex Therapeutics 32.09M 32.23M 2024-09
Daiichi Sankyo JPY 424.35B 67.89B 2025-03
Eisai JPY 147.63B 22.57B 2025-03
Eli Lilly USD 10.5B 624.7M 2025-03
Exelixis USD 536.28M 10.51M 2025-04
Genmab DKK 673M 5.43B 2025-03
Gilead Sciences USD 5.99B 17M 2024-12
GlaxoSmithKline GBP 5.59B 34M 2025-03
Glaxosmithkline GBP 5.6B 94M 2024-12
Incyte USD 985.09M 111.22M 2025-03
Insmed USD 71.54M 6.75M 2025-03
MacroGenics USD 13.86M 94.98M 2024-12
Merck USD 12.77B 849M 2025-03
Moderna USD 17M 403M 2025-03
Novartis USD 10.23B 294M 2024-12
Pfizer USD 11.12B 987M 2025-03
Regeneron Pharmaceuticals USD 2.56B 659.4M 2025-03
Sanofi EUR 7.72B 2.36B 2025-03
Sarepta Therapeutics USD 607.29M 81.18M 2025-03
Takeda JPY 671.32B 55.93B 2025-03
Teva Pharmaceutical Industries USD 1.91B 206M 2025-03
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12
Xencor -45143000 40.69M 2024-09



Seattle Genetics Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Jul 2025.